These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 14991279

  • 1. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.
    Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
    [Abstract] [Full Text] [Related]

  • 2. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.
    Pharmacoeconomics; 2005 Feb; 23(4):377-93. PubMed ID: 15853437
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C.
    Arthritis Rheum; 2002 Dec 15; 47(6):655-61. PubMed ID: 12522841
    [Abstract] [Full Text] [Related]

  • 5. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH.
    Ann Intern Med; 2009 Nov 03; 151(9):612-21. PubMed ID: 19884622
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
    Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I.
    Arthritis Rheum; 2000 Mar 03; 43(3):495-505. PubMed ID: 10728741
    [Abstract] [Full Text] [Related]

  • 10. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA, Foster RH.
    Pharmacoeconomics; 2004 Mar 03; 22(2):107-32. PubMed ID: 14731052
    [Abstract] [Full Text] [Related]

  • 11. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M, Li Gobbi F, Sabadini L, Saviola G, Baiardi P, Manfredi M.
    Int J Immunopathol Pharmacol; 2009 Mar 03; 22(4):1147-52. PubMed ID: 20074482
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P.
    J Rheumatol; 2004 Oct 03; 31(10):1906-11. PubMed ID: 15468352
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea.
    Park SK, Park SH, Lee MY, Park JH, Jeong JH, Lee EK.
    Clin Ther; 2016 Nov 03; 38(11):2430-2446.e3. PubMed ID: 27771177
    [Abstract] [Full Text] [Related]

  • 18. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
    de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE.
    Rheumatology (Oxford); 2016 Dec 03; 55(12):2138-2147. PubMed ID: 27581208
    [Abstract] [Full Text] [Related]

  • 19. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep 03; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 20. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV, Chiou CF, Dubois RW.
    J Manag Care Pharm; 2006 Sep 03; 12(7):555-69. PubMed ID: 16981801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.